Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 20, 2015 16:54 ET | Source: Boston Therapeutics

Boston Therapeutics, Inc. Reports First Quarter Results and Provides Corporate Update

MANCHESTER, NH--(Marketwired - May 20, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that enable people to manage their blood glucose using complex carbohydrate...
March 27, 2015 13:14 ET | Source: Boston Therapeutics

Boston Therapeutics Announces Fourth Quarter and Fiscal Year 2014 Financial Results and Provides Corporate Update

MANCHESTER, NH--(Marketwired - Mar 27, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that enable people to manage their blood glucose using complex carbohydrate...
March 25, 2015 06:36 ET | Source: Boston Therapeutics

Boston Therapeutics' Affiliate Advanced Pharmaceutical Initiates SUGARDOWN(R) Clinical Trial in Hong Kong

MANCHESTER, NH--(Marketwired - Mar 25, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE), affiliate in Hong Kong, Advance Pharmaceutical Company, Ltd. (APC), initiated enrollment of the first...
March 17, 2015 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics and Advance Pharmaceutical Expand sugardown(R) Licensing Agreement to Japan; Increases Number of Asian Countries to 16

MANCHESTER, NH--(Marketwired - Mar 17, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of complex carbohydrates to treat diabetes and inflammatory diseases, and Advance...
January 27, 2015 07:33 ET | Source: Boston Therapeutics

Boston Therapeutics' Hong Kong Affiliate Receives Department of Health Certificate to Initiate SUGARDOWN(R) Clinical Trial

MANCHESTER, NH--(Marketwired - Jan 27, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), received a signed...
January 20, 2015 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics' sugardown(R) Significantly Reduces Glucose, Fructose and Insulin Levels in Sugary Soft Drinks

MANCHESTER, NH--(Marketwired - Jan 20, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE) released additional trial results from its Sydney University study that showed consumption of sugardown®...
January 07, 2015 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics to Present at 8th Annual OneMedForum Conference in San Francisco

MANCHESTER, NH--(Marketwired - Jan 7, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, will be a...
January 06, 2015 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics' sugardown(R) Shown to Reduce Glucose Levels Following Consumption of Sugary Beverages

MANCHESTER, NH--(Marketwired - Jan 6, 2015) - Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, announced that a...
December 10, 2014 08:20 ET | Source: Boston Therapeutics

Boston Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of BTI-320 to Treat Type ll Diabetes and Weight Loss

MANCHESTER, NH--(Marketwired - Dec 10, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, today announced...
November 21, 2014 07:40 ET | Source: Boston Therapeutics

Boston Therapeutics and Advance Pharmaceutical Expand Agreement to Market sugardown(R) in 12 Additional Countries in Asia

MANCHESTER, NH--(Marketwired - Nov 21, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, and...